🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against superbug strains of the infection, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are increasing globally, with estimates suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to develop it.

“This authorization signifies a huge turning point in the management of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Data and Global Access

Based on data published in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared positive views. Having a one-pill regimen such as this is described as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.